Objective: To investigate the relationship between hemorrhagic stroke and use of antiplatelets and warfarin using data from The Health Improvement Network.
METHODS Standard protocol approvals, registrations, and patient consents. The collection of data into THIN was approved by the South-East Multicentre Research Ethics Committee in the United Kingdom.
Study cohort and case ascertainment. The study cohort comprised all patients within the UK medical research database THIN aged 20 to 89 years between January 2000 and December 2008. Patients with a diagnosis of ICH or SAH before their study start date were excluded from the study cohort.
Individuals in the study cohort were followed from the start date until the earliest occurrence of one of the following endpoints: a) hemorrhagic stroke recorded, b) the patient reached 90 years of age, c) patient death, or d) the end of the study period (December 2008) .
For all patients identified with a Read code compatible with hemorrhagic stroke (computer-detected cases), free text comments were requested and the computerized patient profiles were manually reviewed. Cases were discarded during this review in the following instances: the initial diagnostic suspicions were not confirmed, the event was ischemic rather than hemorrhagic, the case was prevalent rather than incident (i.e., not a primary event), the stroke was secondary to trauma, or the patient experienced intracranial extracerebral hemorrhage other than SAH (e.g., subdural hematoma). Those not discarded became potential cases.
At the same time, a validation study in 400 computer-detected cases was performed. This is described in detail elsewhere. 21 In brief, for each computer-detected case, the associated primary care physician (PCP) was asked to fill out a questionnaire and to provide additional details of the episode, including anonymized copies of medical records to confirm the actual status of hemorrhagic stroke among this set of patients. Responses were received for 369 computer-detected cases. Among potential cases for which responses were received, 82% were confirmed as fulfilling the criteria for the study. The proportion of confirmed cases was higher for SAH (91%) than for ICH (73%). However, the proportion of confirmed cases of ICH was improved to 84% if potential cases prescribed antithrombotic or anticoagulant drugs shortly after their ICH episode were excluded, a strategy that was used in the current study.
Nested case-control analysis. To evaluate the risk of hemorrhagic stroke associated with the use of anticoagulants and antiplatelet drugs, we performed a case-control study nested in the study cohort. In this analysis, we included as cases all hemorrhagic strokes, using the date of diagnosis as the index date. A group of 10,000 controls within THIN was randomly selected from the pool of eligible person-time (i.e., using density-based sampling) and was frequency-matched to all cases for sex, age (61 year), and calendar year of diagnosis.
For all cases and controls, we ascertained demographic (e.g., age, sex, body mass index) and lifestyle (e.g., smoking, alcohol intake) factors, as well as general comorbidities at the index date. Additionally, we ascertained exposure to anticoagulants and antiplatelet drugs using separate exposure variables for aspirin, clopidogrel, dipyridamole, and warfarin. We also determined exposure to 2 or more of these drugs simultaneously. Individuals were classified as "current users" if they were taking the drug at the index date or had taken it within the previous 30 days. Everyone else was classified as a "nonuser." Among current users of aspirin and warfarin, we also explored the effect of treatment duration, dose, and international normalized ratio (INR) (warfarin only) on the risk of hemorrhagic stroke. A secondary analysis was performed to examine hemorrhagic stroke risk in new users of low-dose aspirin; to meet the criteria for this group, patients must have started low-dose aspirin during the study period and must have had at least 1 year free from aspirin treatment before this time point.
Unconditional regression analyses were run separately for ICH and SAH to estimate odds ratios (ORs), together with 95% confidence intervals (CIs). ORs presented are compared with not having the condition or lifestyle factor, or not using the drug or drugs in question (e.g., nonuser). The fully adjusted model included frequency-matched variables (i.e., age, sex, and calendar year) and the following covariates: smoking, alcohol, body mass index, hypertension, and health services utilization (PCP visits, referrals, and hospitalizations). All analyses were performed using Stata SE 10.0 (StataCorp, College Station, TX).
RESULTS
Within THIN, a cohort of 2,110,327 individuals fulfilling the inclusion criteria was identified. They were followed for an average of 5.8 years, and 4,330 cases had a Read code suggesting hemorrhagic stroke (computer-detected cases). After manual review and validation of a random sample with PCPs, the final numbers of ICH and SAH cases for the analyses were 1,797 and 1,340, respectively.
Demographics and lifestyle factors. The demographics of ICH cases differed greatly from those of SAH cases: mean age at diagnosis was 70.8 years for ICH and 57.7 years for SAH. The corresponding proportions of females were 48.9% and 62.4%, respectively. These differences in demographics mean that crude estimates of association are essentially invalid, because controls were frequency-matched to all hemorrhagic stroke cases (i.e., ICH and SAH cases combined) and will be, by design, younger than ICH cases and older than SAH cases. Therefore, only adjusted estimates should be considered. All estimates referred to hereafter are from the fully adjusted model. Table 1 shows the frequency of comorbidity and lifestyle factors among ICH cases, SAH cases, and controls. Having a history of ischemic stroke was the strongest predictor of ICH (OR 2.65, 95% CI 2.27-3.09).
Smoking was the strongest predictor of SAH (OR 3.02, 95% CI 2.61-3.49). Health services utilization in the year before the event showed a positive association with risk of both ICH and SAH; having one or more hospitalizations increased the risk by a similar amount for both ICH and SAH (OR 1.91, 95% CI 1.66-2.20 for ICH; OR 1.98, 95% CI 1.66-2.37 for SAH) compared with no hospitalizations.
Effect of antiplatelet use on risk of hemorrhagic stroke.
The OR for ICH among current users of aspirin was 1.06 (95% CI 0.93-1.21), and 0.82 (95% CI 0.67-1.00) for SAH (table 2). The short-term use of antiplatelets (,3 months of use) was associated with a small increased risk of ICH (OR 1.59, 95% CI 1.05-2.40). No increase in hemorrhagic stroke risk was noted when Clopidogrel was not associated with increased risk of ICH or SAH. The risk was elevated among users of dipyridamole compared with untreated individuals, although these results were based on a very small number of individuals exposed (table 2) .
Effect of warfarin on risk of hemorrhagic stroke. Current users of warfarin experienced a clearly increased (table 3, figure e-2) ; individuals with INR ,2.5 did not experience any increased risk of hemorrhagic stroke, but those with INR between 3.0 and 3.9 experienced a greatly increased risk of ICH (OR 5.61, 95% CI 3.07-10.23; p-trend , 0.001) compared with no therapy. Individuals with an INR of $3 had an OR of 7.01 (95% CI 4.10-11.99) for ICH and an OR of 2.64 (95% CI 0.95-7.35) for SAH.
Effect of simultaneous use of antithrombotics on risk of hemorrhagic stroke. The association between the simultaneous use of different antiplatelet drugs and/or warfarin and the risk of hemorrhagic stroke was also assessed. Use of aspirin alone was associated with a negligible increased risk of hemorrhagic stroke (OR for ICH 1.18, 95% CI 1.03-1.37; OR for SAH 0.83, 95% CI 0.67-1.03) compared with no therapy (figure 1). The combination of aspirin and clopidogrel was not associated with an increased risk relative to no therapy (table 4) . By contrast, the simultaneous use of aspirin and dipyridamole was associated with an increased risk of both types of hemorrhagic stroke (OR for ICH 2.97, 95% CI 1.80-4.90; OR for SAH 2.37, 95% CI 1.02-5.47) compared with no therapy. The risk of ICH associated with warfarin use did not vary between when it was used alone and when it was used in combination with a single antiplatelet agent (table 4, figure 1 ). However, in the few instances when warfarin was used in combination with more than one antiplatelet agent (n 5 4), the risk of ICH was greatly increased (OR 6.98, 95% CI 1.25-39.12) compared with no therapy.
The risk of hemorrhagic stroke associated with dipyridamole alone was similar for ICH (OR 1.94, 95% CI 1.01-3.74) and SAH (OR 1.93, 95% CI 0.77-4.85) compared with no therapy (table 4, figure 1 ). However, it should be noted that use of dipyridamole was most common among individuals with prior cerebrovascular disease (i.e., ischemic stroke and TIA), and that there was no increased risk of ICH among dipyridamole users within this subgroup of individuals (OR for ICH 0.71, 95% CI 0.30-1.68; OR for SAH 1.64, 95% CI 0.50-5.40) relative to no therapy (table e-1). DISCUSSION This study is the first to examine the effects of antithrombotic drugs on the risk of both ICH and SAH in the general population. Analysis of data from more than 3,100 patients with hemorrhagic stroke in the UK THIN database has shown that aspirin use is not associated with increased risk of hemorrhagic stroke, compared with no therapy. Importantly, use of warfarin conferred a marked increased risk of ICH and a moderately increased risk of SAH compared with no therapy.
Antithrombotic therapy is well established for the prevention of stroke in patients with atrial fibrillation; however, the use of anticoagulants and antiplatelet drugs must be balanced with the associated increased risk of bleeding events. To aid clinicians to assess the risks and benefits of antithrombotic therapy in this patient population, several stroke and bleeding risk stratifications have been developed. Based on data from the EuroHeart survey, the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history, labile INR, elderly, drugs/alcohol concomitantly) system was generated, whereby the use of antithrombotic therapy is cautioned in patients with 3 or more of these characteristics because of a high risk of bleeding. 22 Our study revealed that hypertension, a history of stroke, increased INR, and heavy use of alcohol were factors associated with increased risk of hemorrhagic stroke, suggesting the need for further consideration of these characteristics when assessing the risk/benefit profile of antithrombotic therapy in this patient population. This large population-based study confirms that use of antiplatelet drugs is not associated with a significantly increased risk of hemorrhagic stroke compared with no therapy. In fact, very long-term use of aspirin was found to confer a small decrease in the risk of SAH, compared with no therapy. Such findings are in line with results of previous studies that showed a low risk of ICH in lowdose aspirin users. 12 A case-control study nested within the International Study of Unruptured Intracranial Aneurysms found that use of aspirin 3 or more times per week reduced the risk of SAH considerably compared with no aspirin (OR 0.40, 95% CI 0.18-0.87). 18 This finding was attributed to a possible inhibitory effect of aspirin on the inflammatory cascade implicated in intracranial aneurysm formation 23, 24 -the cause of SAH in approximately 85% of cases. [25] [26] [27] The fact that the trend toward reduced risk of SAH in the current study was particularly pronounced in patients who had been receiving aspirin for more than 3 years (OR 0.63, 95% CI 0.45-0.90) raises the possibility that long-term aspirin use may have a protective effect on aneurysm rupture, as suggested by Hasan et al. 18 The effect of other antiplatelet drugs on hemorrhagic stroke risk was also evaluated. Use of clopidogrel was not associated with an increased risk of ICH or SAH compared with no therapy, although these analyses were based on a limited number of patients. An increased risk of hemorrhagic stroke was observed in patients taking dipyridamole, although this should be interpreted with caution. The registered indication for dipyridamole is secondary prevention of stroke in patients with a history of stroke or TIA. Thus, the observed increase in hemorrhagic stroke among dipyridamole users, even after adjustment for known confounders, probably reflects the fact that the drug acts as a marker of conditions that are known predictors of ICH, rather than indicating a greater excess risk of ICH/SAH in users of this drug relative to users of other antiplatelet drugs. The finding that risk of hemorrhagic stroke was not elevated among dipyridamole users relative to no therapy in a subgroup of individuals with a history of cerebrovascular disease lends support to this interpretation.
An association between warfarin use and ICH has been reported previously 5, 10, 17 ; however, data on the effect of anticoagulation on SAH risk have been scarce, with studies reporting conflicting results. 18, 19 The current analysis suggests that warfarin use is associated with an increased risk of both ICH and SAH compared with no therapy, regardless of the duration of treatment. In patients taking warfarin, an INR above the recommended range was a strong predictor of the risk of hemorrhagic stroke in this study. This underscores the importance of routine monitoring of the INR and effective dose adjustment in patients receiving warfarin. Unfortunately, many patients receiving warfarin fall outside of the optimal range of coagulation: a review of 24 anticoagulation Effect of APs and warfarin on risk of ICH and SAH Odds ratios with 95% confidence intervals for ICH and SAH for each treatment category relative to no treatment. AP 5 antiplatelet; ICH 5 intracerebral hemorrhage; SAH 5 subarachnoid hemorrhage.
studies showed that patients receiving warfarin or other vitamin K antagonists who were monitored in usual care (community-and hospital-based) settings were within target range (INR 2-3) for only 56% of the time, and those monitored at specialist anticoagulation clinics were in range for only 65% of the time. 28 In the current study population, individuals receiving warfarin were within the target range 69% of the time, and 15% had INR values .3.
Recent studies have indicated that the use of anticoagulants in combination with 1 (dual therapy) or 2 (triple therapy) antiplatelet drugs, or use of 2 antiplatelet drugs alone, may increase the risk of bleeding. In a Danish registry-based study, dual and triple therapy increased the risk of all bleeding (a composite of nonfatal bleeding, fatal bleeding, intracranial bleeding, airway bleeding, gastrointestinal bleeding, and urinary tract bleeding) more than 3-fold compared with warfarin monotherapy. 29 However, when intracranial bleeding was evaluated in isolation, the comparative risk conferred by triple therapy (1.0% per year) and dual therapy (0.8% per year), as compared with warfarin monotherapy (0.6% per year), was similar. The current finding that ICH risk is of similar magnitude in patients receiving warfarin monotherapy and dual therapy is in line with the Danish study. 29 Nevertheless, it is clear that additional quantification of hemorrhagic stroke risk in this patient population would be worthwhile, especially given that the only well-documented evidence for combined anticoagulant and antiplatelet therapy showing increased antithrombotic efficacy compared with monotherapy is for the treatment of patients with prosthetic heart valves. 30 New oral anticoagulants that do not require INR monitoring are now available. Analyses of randomized clinical trial data indicate that the risk of intracranial hemorrhage is lower in patients receiving rivaroxaban, apixaban, or dabigatran compared with warfarin. [31] [32] [33] [34] Based on the findings described, it will be of interest to investigate to what extent the use of new oral anticoagulants is associated with hemorrhagic stroke in the general population. A major strength of this study is that use of THIN has allowed analysis of an extensive sample that is representative of the UK primary care population and has age and sex distributions similar to those of the general population. A potential limitation of the study is that patients may have been misclassified as having a hemorrhagic stroke in some cases; however, the internal validation study of computer-detected cases showed an overall confirmation rate of correct classification of 82%. 21 Another potential limitation is the inclusion of possible confounding variables, which is a limitation of all observational studies. Attempts have been made to control for this as much as possible by using a multivariate analysis adjusted for several relevant covariates and demographic factors. Nevertheless, some unidentified minor confounding factors may still remain.
This analysis has shown that aspirin use does not carry an increased risk of ICH relative to no therapy and was found to confer a small decrease in the risk of SAH, particularly after prolonged use. These findings are compatible with a protective effect of long-term, low-dose aspirin use on SAH. By contrast, warfarin use is associated with a much higher risk of ICH compared with no therapy, with a marked dose effect. To a lesser extent, warfarin is also associated with an increased risk of SAH compared with no therapy.
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